Citations

Clear

6055 citation(s) found for "Vu, Peter".

Antimicrobial-induced neutropenia in patients receiving OPAT or COpAT: A large multisite retrospective cohort study
Abel, A. L. , Saleh, Omar Abu , Cole, Kristin, Jensen, Kelsey , Martin, Peter , Pertzborn, Margaret , Virk, Abinash , Mara, Kristin C. , Edwards, Megan , Van Abel, Amy, Abu Saleh, Omar , Challener, Doug, Jensen, Kelsey , Mara, Kristin C , Edwards, Megan, Challener, Douglas W. , Rivera, Christina G.

Mayo Clinic

American Journal of Health-System Pharmacy | April 9, 2025 | Volume: 82 | Issue: 18 | Pages: 970-978

10.1093/ajhp/zxaf086 | PMID 40202429 Get It

Abstract Purpose Data regarding the incidence, onset, and management of complex outpatient antimicrobial therapy–induced neutropenia (COIN) are limited, and pharmacist involvement in COIN management has not been reported. This report describes the incidence, onset, and management of COIN at a large academic medical center. Methods This multisite retrospective cohort study examined adult patients undergoing serum laboratory monitoring for antimicrobials over a 4-year period. Patients receiving chemotherapy or immunosuppressants were excluded. Data collected included the antimicrobial regimen, complete blood count, duration of antimicrobial therapy until outcome occurrence, infectious syndrome, type of intervention, outcome, and pharmacist involvement. Logistic regression was used to assess risk factors for COIN incidence. The primary outcome was the incidence of COIN by antimicrobial drug. Results From 4,261 treatment episodes, 161 cases of COIN were identified (3.8% COIN incidence). The most common antimicrobials associated with COIN were intravenous piperacillin/tazobactam, cefepime, and meropenem. The majority of COIN events were attributed to a combination of at least 2 antimicrobials. Piperacillin/tazobactam was significantly associated with higher odds of developing COIN (odds ratio [OR], 1.86; 95% confidence interval [CI], 1.04-3.34; P = 0.038), whereas ertapenem was associated with significantly lower odds of COIN (OR, 0.43; 95% CI, 0.24-0.77; P = 0.005). The median time to neutropenia diagnosis was 22 days (interquartile range, 14-29 days) from the time of inpatient antimicrobial start. Intervention for COIN occurred in 66.5% of cases, with neutrophil count recovering in 96.9% of these patients. Clinical pharmacists initiated 74.8% of interventions. Conclusion COIN can be effectively identified and managed by a multidisciplinary team reviewing routine laboratory monitoring, enabling most patients to safely complete antimicrobial treatment.
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025
Lin, Daniel W. , Feldman, Darren R., Aggarwal, Rahul , Drakaki, Alexandra , Eggener, Scott E. , Humphrey, Peter A. , Leuva, Harshraj , Levine, Ellis G., Maughan, Benjamin L. , Reichert, Zachery R. , Rwigema, Jean‐Claude M. , Shah, Sumit, Singla, Nirmish, Sircar, Kanishka , Zhumkhawala, Ali , Sliker, Bailee , Gilligan, Timothy D. , Adra, Nabil , Bagrodia, Aditya , Yamoah, Kosj , Chandrasekar, Thenappan , Costa, Daniel Nobrega da , Drakaki, Alexandra , Emamekhoo, Hamid , Geynisman, Daniel M. , Graham, Laura , Luckenbaugh, Amy N. , McGregor, Bradley A. , Monk, Paul , Picus, Joel , Pierorazio, Phillip , Rais‐Bahrami, Soroush , Saylor, Philip J. , Shah, Ankeet , Shah, Sumit, VanderWeele, David James , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2025 | Volume: 23 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.0018 | PMID 40203876 Get It

The NCCN Guidelines for Testicular Cancer provide recommendations for the multidisciplinary approach to the diagnostic workup, treatment, and follow-up for testicular germ cell tumors, including both seminoma and nonseminoma. These NCCN Guidelines Insights discuss the current treatment recommendations and supporting clinical data for seminomas as presented in Version 2.2025 of the NCCN Guidelines for Testicular Cancer.
Bone Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Biermann, J. Sybil, Boles, Sarah G , Brigman, Brian E. , Callan, Alexandra K. , Cranmer, Lee D., Davis, Jessica , Donnelly, Eric D. , Ferguson, Michael J. , Graham, Ann, Groundland, John , Hess, Matthew, Hiniker, Susan M. , Hoover‐Regan, Margo , Jonard, Brandon , Lindskog, Dieter M. , Mayerson, Joel , McGarry, Sean V., Olson, Daniel J. , Rose, Peter S. , Santana, Victor M. , Satcher, Robert L. , Schwartz, Herbert S. , Shulman, Rebecca M. , Wustrack, Rosanna , Yoon, Janet, Hang, Lisa E., Jones, Frankie, Sansone, Nicholas, Lyons, Megan , Hirbe, Angela C. , Ahlawat, Shivani , Bernthal, Nicholas M , Binitie, Odion , Cipriano, Cara A. , Cranmer, Lee D. , Graham, Ann, Hess, Matthew, Hornick, Jason L. , Kuechle, Joseph , Morris, Carol D. , Thorpe, Steven W. , Wilky, Breelyn A , Lyons, Megan

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 9, 2025 | Volume: 23 | Issue: 4 | Pages: No page available

10.6004/jnccn.2025.0017 | PMID 40203873 Get It

Ewing sarcoma and osteosarcoma constitute 36% of all primary bone cancers. However, these 2 subtypes represent the most commonly diagnosed bone cancer types in the pediatric and adolescent population. Although still largely unknown, certain genetic mutations, rearrangements, and/or predisposition syndromes likely play a role in the pathogenesis of bone cancer. Osteosarcoma may also develop as a direct result of the long-term side effects of radiation therapy. With the implementation of a multimodality approach to treatment, including multiagent neoadjuvant and adjuvant chemotherapy regimens, targeted therapy options, surgery, and radiation, individuals with Ewing sarcoma and osteosarcoma are showing higher cure rates and improved overall survival. The NCCN Guidelines for Bone Cancer provide a consensus and evidence-based framework for the workup, management, and surveillance of local and recurrent/metastatic disease.
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment
Dima, Danai , Afrough, Aimaz , Goel, Utkarsh , Grajales‐Cruz, Ariel , Khouri, Jack , Julian, Kelley , Banerjee, Rahul , Razzo, Beatrice M. , Ferreri, Christopher J. , Martinez, Mariola Alejandra Vazquez, Davis, James A. , Sannareddy, Aishwarya , Raza, Shahzad , Portuguese, Andrew J. , Gaballa, Mahmoud , Rana, Masooma , DeJarnette, Shaun, Gonzalez, Rebecca , Mikkilineni, Lekha , Hosoya, Hitomi , Ouchveridze, Evguenia, Shune, Leyla , Lin, Yi , Sborov, Douglas W. , Anderson, Larry D. , Cowan, Andrew J., Patel, Krina K. , Voorhees, Peter M. , Sidana, Surbhi , Hansen, Doris K., Susanibar-Adaniya, Sandra P. , Grajales-Cruz, Ariel F , Banerjee, Rahul , Vazquez-Martinez, Mariola A , Davis, James A , Portuguese, Andrew J , Rana, Masooma S , Lieberman-Cribbin, Alex , Chen, Anna , Herr, Megan M. , Anwer, Faiz , Sborov, Douglas W , Garfall, Alfred L , Lee, Hans C , Anderson, Larry D , Patel, Krina , Voorhees, Peter , Sidana, Surbhi , Dima, Danai , Raza, Shahzad , Hosoya, Hitomi , Julian, Kelley L , Susanibar-Adaniya, Sandra P , Pasvolsky, Oren , Vazquez‐Martinez, Mariola , Puglianini, Omar Castañeda , Ouchveridze, Evguenia, Kaur, Gurbakhash , Rossi, Adriana , Anwer, Faiz , Richard, Shambavi , Baz, Rachid , Garfall, Alfred L. , Lee, Hans C. , Hansen, Doris K. , Atrash, Shebli

Mayo Clinic

Blood Advances | April 8, 2025 | Volume: 9 | Issue: 14 | Pages: 3408-3417

10.1182/bloodadvances.2025016059 | PMID 40198766 Get It

Abstract Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well characterized, given the exclusion of these patients from clinical trials. Herein, we evaluated patients with relapsed/refractory multiple myeloma and RI treated with standard-of-care teclistamab. RI was defined as creatinine clearance (CrCl) <40 mL/min. CrCl <30 mL/min or dialysis dependence was defined as severe RI. Of the 384 included patients, 81 (21%) had RI, including 45 (18%) with severe RI, and 18 (5%) on dialysis. Patients with RI were more likely to be older (median age, 71 vs 67 years; P = .002) and have a higher median number of previous lines of therapy (7 vs 6; P = .04). Rates and severity of cytokine release syndrome (51% vs 59%; grade ≥3: 1.2% vs 1%) and immune effector cell–associated neurotoxicity syndrome (16% vs 13%; grade ≥3: 2.5% vs 2.6%) were similar in patients with and without RI, respectively. Patients with RI had higher baseline and day 30 post-teclistamab grade ≥3 anemia and grade ≥3 thrombocytopenia. Renal function did not worsen after teclistamab initiation in most patients with RI outside of the context of disease progression. Overall response rate (52% vs 56%; P = .61) and survival outcomes (median progression-free survival, 4.6 vs 6.5 months; P = .62) were comparable in patients with and without RI, respectively, after a median follow-up of 9.9 months. No differences in overall survival or non-relapse mortality were noted. Our findings suggest that treatment with teclistamab is feasible in patients with RI, including those on dialysis, with a similar safety and efficacy profile to patients without RI.
A Novel Case of Nerve Biopsy Proven Wild Type Transthyretin Amyloidosis (P12-11.014)
Daley, Catherine, Dyck, Peter James , Skolka, Michael P

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000208489 Get It

Network Meta-Analysis Comparing Efficacy and Safety Outcomes of Atogepant, Rimegepant, and Galcanezumab in Patients with Episodic Migraine After Including CHALLENGE-MIG Trial (P9-12.007)
Gandhi, Pranav , Lalla, Anjana, McAllister, Peter , Bilchik, Tanya R., Rowe, David A. , Piron, Cristiano, Kelton, Kari , Ailani, Jessica , Lalla, Anjana, Nahas, Stephanie J. , Rowe, David, Singh, Rashmi B. Halker

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210714 Get It

Secondary Neurolymphomatosis after 11 Years of Remission of CNS Lymphoma: A Case Report (P7-11.005)
Riley, H D, Chen, Jie , Dyck, Peter James , Thaisetthawatkul, Pariwat , Riley, Haley

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211164 Get It

Higher Atrial Fibrillation Probability and Delta Age Computed by Artificial Intelligence-ECG Models Predict More Cardiovascular Events in Patients with Migraine (P4-12.001)
Zhang, Nan , Mangold, Kathryn, Attia, Itzhak Zachi, Friedman, Paul A. , Yang, Ping , Chao, Chieh‐Ju , López-Jiménez, Francisco , Attia, Itzhak Zachi, Noseworthy, Peter A. , Chiang, Chia‐Chun

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000211054 Get It

Two Cases of HNPP Masquerading as CIDP (P11-11.004)
Jedras, Mark, Dyck, Peter James , Thaisetthawatkul, Pariwat

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210445 Get It

Interim Analysis of CONFIDENCE: A ProspeCtive ObservatioNal Study with Acute Treatment oF rImegepant ODT on ConsistENcy, SatisfaCtion and Tolerability of TrEatment in the Real World (P10-12.001)
Galabova, Boryana, Abraham, Lucy , Urani, Alexandre , Lambru, Giorgio , Lipton, Richard B. , Goadsby, Peter J. , Pozo‐Rosich, Patricia , Schwedt, Todd J. , Dai, Feng , Blakeman, Karin Hygge

Mayo Clinic

Neurology | April 7, 2025 | Volume: 104 | Issue: 7_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000210369 Get It